Bristol-Myers Squibb Co. (BMY)
Loading...
Symbols:
BMY Forum Topics
- All Comments on BMY
- General Discussion on BMY
- Fannie & Freddie Bailout? - Fast Money Recap (9/5/08) [view article]
- 5 Potential Buyout Targets in Biotech - Barron's [view article]
- Big Pharma Pipeline: Why So Dry? [view article]
- Biotech Outlook: M&A Will Continue [view article]
- China's Hepatitis B Market to Double by 2012 [view article]
- Time to Invest in Pharmaceuticals? [view article]
- Five Biopharma Companies Drop on Negative Drug News [view article]
- The Top Dividend Paying ETFs and Stocks [view article]
- Imclone Systems: No Shame, No Gain [view article]
- Updates on the Healthcare/Biotech Mergers [view article]
- Companies With Recent, Innovative Product Approvals vs. Healthcare ETFs [view article]
- Big Pharma’s Healthy Appetite for Acquisitions [view article]
loading ...Recent BMY Articles
- Fannie & Freddie Bailout? - Fast Money Recap (9/5/08)
- Big Pharma Pipeline: Why So Dry?
- Biotech Outlook: M&A Will Continue
- China's Hepatitis B Market to Double by 2012
- Five Biopharma Companies Drop on Negative Drug News
- 2008 Q2 Portfolio Holdings: Berkowitz, Rodriguez & Pabrai
- Bristol-Myers Ponies Up for Elotuzumab
- AstraZeneca Gives FluMist Spray a Shot in the Arm
- Time to Invest in Pharmaceuticals?
- 5 Potential Buyout Targets in Biotech - Barron's
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Time to Invest in Pharmaceuticals? [view article]
User 245013 - I'm not a journalist. And yes I am aware that it takes many years of research and hundreds of millions in development costs to bring a drug to market. Certainly many drugs remain unprofitable for many years, and sometimes their entire lifetime post-launch.Hence why many large pharmas are acquiring or partnering with research facilities and other drug companies. Reply
Time to Invest in Pharmaceuticals? [view article]
Howard,Good article, except for one point. It takes about $1 billion to get a drug launced AND THEN it costs a few pennies to produce. Just trying to keep you journalists honest (a toughjob nowadays). Reply
Time to Invest in Pharmaceuticals? [view article]
Everyone wants universal healthcare, inexpensive/affordable healthcare and quality healthcare. You can only have two of them at any one time. To increase one it is at the expense of one or both of the other two. More and more doctors are beginning to refuse government sponsored health care programs, e.g. Medicare. Too much paperwork and too little pay. ReplyTime to Invest in Pharmaceuticals? [view article]
one of my major concerns about this upcoming year is how the election will pan out. If universal healthcare turns out to be a real possibility, then pharma companies are going to find it even tougher as their biggest customer will be the government. Reply5 Potential Buyout Targets in Biotech - Barron's [view article]
Vertex is possible depending on how the competition with Bocepravir plays out. Still looks to have a first to market advantage, and follow on versions might have better dosing schedule.UTHR is too expensive, unless bought out by another biotech like GILD using stock. PAH is becoming a very competitive space, and cost competition is coming. UTHR benefitted early on from a lack of choices, but their earnings growth rate is topping out now.
ALXN, too expensive for cash buyers, plus a political nightmare in the upcoming budget wars since Soliris may be the most expensive drug ever (nearly half a million dollars a year). What pharma wants that headache?
ONXX, once again expensive for a cash acquirer, and the industry pipeline is bulging with small molecule kinase inhibitors at practically every step in the tumor growth pathways. Patent life is irrelevant for Nexavar, better drugs are available now and more will be along soon.
AMLN, possible, but Byetta has been expensive to promote and slow to gain a significant foothold. Exenatide LAR will probably face the same challenges, making the ROI questionable for any bid that includes the substantial acquisition premium expected by the market these days. Reply
nvestor
5 Potential Buyout Targets in Biotech - Barron's [view article]
There are many small and microcap medical companies that many of these large pharmas could buy without sneezing. One is DCTH which could bring new life to drugs new and old. Reply5 Potential Buyout Targets in Biotech - Barron's [view article]
Unfortunately, American Big Pharma companies became more marketing organizations rather than new drug development companies.It appears that, at the time when companies like ImClone are developing new super-drugs like Erbitux capable of savings thousands of lives, the Wall Street green-mailers, speculators, extortionists and biotech companies stock price manipulations greatly endanger new drugs development process doing great disservice to people all around world.
The above article is discussing how Big Pharma, with their zillion-dollars executives compensation packages, has failed in development of drugs and now is in a process of ripping off the most innovative and successful biotech companies and its shareholders.
These Big Pharma acquisition activities add nothing to new drug development but greatly endanger so many lives that could be saved by new drugs.
Reply
ul
5 Potential Buyout Targets in Biotech - Barron's [view article]
I would add to that list BIIB...considering the absurd sh/pr hit which Biogen has taken on Tysabri and the fact that Carl Icahn is accumulating. ELN is of course caught up in the same recent events and is also a prime target for acquisition by either Wyeth (WYE) or Biogen Idec (BIIB).Add Dendreon (DNDN) to the list if their interim analysis of Provenge (October estimate) for end-stage prostate cancer is sufficiently positive to allow for immediate trial cessation and refiling of BLA...I would give them roughly a 75% chance of sufficient success at the interim btw. Reply
5 Potential Buyout Targets in Biotech - Barron's [view article]
The patent expiration problems of large pharma are well know. This article would have added value if the specific reasons why the target companies were potential takeovers would have given substance to it.In this day where primary research is virtually missing and everyone seems to be peddling their portfolio, it would be refreshing to get sound reasoning backed by substantive facts rather than mere opinions which are worth exactly what you pay for them. Reply
Imclone Systems: No Shame, No Gain [view article]
Hopefully, Merck Kgaa will enter the picture to make a bid. IMCL would be better off --even if it was at a lower price. They have a proven track record in getting things done.On Aug 08 01:06 AM nova wrote:
> "IMCL still needs BMY more than BMY needs IMCL." Why? What for? Merck
> KGaA tells everybody that they were and are ready to buyout Erbitux
> franchise from BMY at any time.
>
> For the last 6 yrs, BMY did not execute any single Erbitux registration
> quality clinical trial. None. All Erbitux high quality clinical trial
> were executed by Merck KGaA.
>
> BMY's marketing of Erbitux is a total disgrace:
> - It highly overpriced Erbitux following its approval in America.
> Merck KGaA priced Erbitux at half of BMY price and sells much more
> Erbitux than BMY. Merck KGaA expects that its Erbitux sale in two
> years will exceed $2B.
> - IMCL had to create and engage its own sale force to move Erbitux
> sale.
> - The latest clinical trials indicate that Erbitux efficacy in wild-Kras
> metastatic colorectal patients is much more superior to Avastin but
> BMY has done nothing to bring this message to medical and patients
> communities.
>
> IMCL likes to get rid off BMY. Hopefully, it will happen soon. Reply
Updates on the Healthcare/Biotech Mergers [view article]
Mike Huckman,Your incompetence and ignorance are on par with your stupidity.
You are doing great disservice to both retail investment and patients communities. Thanks to you and you alike, good many patients do not get the right medical treatment they so badly need.
Your promotion of Genentech's Avastin is just disgusting. This highly expensive and highly ineffective drug does not offer any survival benefits to colorectal, lung and breast cancer patients when used with the latest chemotherapy.
At the same, ImClone's Erbitux has shown substantial survival benefits in many settings:
- 3rd-line metastatic colorectal cancer survival benefits were increased by 5 months in wild-Kras patient population
- Head & Neck cancer patients saw their survival benefits increased by 2 years being treated by Erbitux combined with radiation
- Non-small cell lung cancer patients survival benefits were increased by 8 weeks for very diverse and difficult to treat Caucasian patient population.
Very fortunately for American cancer patients, American oncology community pays close to no attention to your highly inaccurate, biased and quite often dishonest commentaries.
To call ImClone Phase III clinical trials to develop so much needed treatments capable of helping to women with breast cancer "a not-so-veiled negotiating tactic" is just outright disgusting. Reply
Companies With Recent, Innovative Product Approvals vs. Healthcare ETFs [view article]
but this is hindsightand investment is foresight Reply
Big Pharma’s Healthy Appetite for Acquisitions [view article]
Why should Carl Icahn accept Bristol's offer at $60? There are no reasons for it at all.18 months ago, Icahn has blocked ImClone sale to Sanofi for $36. Now, Bristol offers $60.
Icahn has a strong hand. He can tell to major ImClone shareholders: a $60-offer is not good but, in another 12-18 months, I might be able to get a new offer twice as big.
As Imclone's shareholder, I will go for it!
Reply
Imclone Systems: No Shame, No Gain [view article]
In spite of the media and some analysts claim that Carl must sell IMCL now, it is not true. Why in world will Carl sell IMCL for $60 thinking he can get much more later?1.5 yrs ago, Carl was accused of preventing a sale of ImClone to Sanofi for $36. Now, Carl gets a new offer from BMY for $60.
Again Carl can successfully claim the BMY offer is not adequate as it was 1.5 yrs ago. Therefore, Carl has a strong hand in this game.
Speaking about Merck KGaA.
One year ago, Merck lost 11F8 arbitration to ImClone. 11F8 is a fully-human, second-generation EGFr-drug, potentially more superior to Erbitux. Merck has no claims to it in its territory. Presently, Merck pays 9.5% of Erbitux revenues to ImClone and expect Erbitux revenues in excess of $2B in just 2 years.
If Merck alone or together with BMY participates in a hostile takeover of ImClone then chances for a future kiss up with ImClone are zero.
Now about BMY.
BMY is a loser. Its stock lost a half of its value in the last 12 months. Two weeks ago, BMY and Sanofi lost Plavix's patent in EU. Consequently, BMY might go to low teens. So, nobody wants BMY stock. BMY has $4.4B in cash following selling some of its assets. It is all what BMY can afford to spend on buying IMCL.
What is ImClone real value? Nobody really knows before seeing Crystal, OPUS, 099 as well as pipeline clinical trials to be available in the next 4-8 months.
If the results are good, IMCL's market cap will be well North from $10B or well over $120+ PPS.
I am ready to wait. What will Carl do? I don't know but he has a lot of these clinical data already! Reply
Imclone Systems: No Shame, No Gain [view article]
nova,"IMCL likes to get rid off BMY. Hopefully, it will happen soon"
So are we going to see IMCL offer BMY to buy back 14.4M shares at $60.00? How's about a 'you by me out or I buy you out' pricing? What do you think IMCL would offer? For that matter, how much would Merck offer both?
No matter how you cut it, you are still at the 60 mark, just BMY beat MRK to the punch line. If the BMY offer was so under priced then MRK would have jumped by now.
As an aside, Icahn was annoyed that BMY may have used inside information regarding how management was looking for ways to CREATE shareholder value. Reading in between the lines this means that IMCL wasn't going to get there on its own and there is a need to get creative!
Not saying that IMCL is a bad company or anything close to that, just the valuation has to be real this time, no hype. Patents are like options, the clock doesn't stop ticking and you can be sure that the likes of TEVA is watching the clock. As time goes on, the value drops as there is less time left etc.
As stated, BMY is in no rush to conclude a deal.
CrossProfit Reply